OTCPK:FSNU.F

Stock Analysis Report

Executive Summary

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide.

Snowflake

Fundamentals

Undervalued established dividend payer.


Similar Companies

Share Price & News

How has Fresenius SE KGaA's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:FSNU.F

0.1%

US Healthcare

0.8%

US Market


1 Year Return

n/a

OTCPK:FSNU.F

-8.4%

US Healthcare

1.9%

US Market

No trading data on FSNU.F.

No trading data on FSNU.F.


Share holder returns

FSNU.FIndustryMarket
7 Day0%0.1%0.8%
30 Day1.1%-1.4%3.4%
90 Day-9.7%-0.7%2.1%
1 Yearn/a-7.0%-8.4%4.2%1.9%
3 Year-37.9%-37.9%30.6%25.3%46.7%37.2%
5 Year-4.0%-4.0%64.9%55.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Fresenius SE KGaA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Fresenius SE KGaA undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Fresenius SE KGaA's share price is below the future cash flow value, and at a moderate discount (> 20%).

Fresenius SE KGaA's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Fresenius SE KGaA is good value based on earnings compared to the US Healthcare industry average.

Fresenius SE KGaA is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Fresenius SE KGaA is poor value based on expected growth next year.


Price Based on Value of Assets

Fresenius SE KGaA is good value based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is Fresenius SE KGaA expected to perform in the next 1 to 3 years based on estimates from 21 analysts?

9.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Fresenius SE KGaA's revenue is expected to grow by 5.5% yearly, however this is not considered high growth (20% yearly).

Fresenius SE KGaA's earnings are expected to grow by 9.9% yearly, however this is not considered high growth (20% yearly).

Fresenius SE KGaA's revenue growth is positive but not above the United States of America market average.

Fresenius SE KGaA's earnings growth is positive but not above the United States of America market average.

Fresenius SE KGaA's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Fresenius SE KGaA is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Fresenius SE KGaA performed over the past 5 years?

13.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Fresenius SE KGaA's year on year earnings growth rate has been positive over the past 5 years.

Fresenius SE KGaA's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Fresenius SE KGaA's 1-year earnings growth is negative, it can't be compared to the US Healthcare industry average.


Return on Equity

Fresenius SE KGaA has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Fresenius SE KGaA used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

Fresenius SE KGaA's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Fresenius SE KGaA's financial position?


Financial Position Analysis

Fresenius SE KGaA is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Fresenius SE KGaA's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Fresenius SE KGaA's level of debt (81.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (102.3% vs 81.5% today).

Debt is not well covered by operating cash flow (19.2%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 6.8x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are 0.7x debt.


Next Steps

Dividend

What is Fresenius SE KGaA's current dividend yield, its reliability and sustainability?

1.93%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Fresenius SE KGaA's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.43%).

Fresenius SE KGaA's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (4.2x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (4.4x coverage).


Next Steps

Management

What is the CEO of Fresenius SE KGaA's salary, the management and board of directors tenure and is there insider trading?

6.7yrs

Average management tenure


CEO

Stephan Sturm (56yo)

3.2yrs

Tenure

€6,025,000

Compensation

Mr. Stephan Sturm serves as Chairman of the Management Board, Chief Executive Officer and President at Fresenius Management SE, the General Partner of Fresenius SE & Co KGaA since July 1, 2016 and its Memb ...


CEO Compensation Analysis

Stephan's remuneration is lower than average for companies of similar size in United States of America.

Stephan's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

6.7yrs

Average Tenure

55yo

Average Age

The average tenure for the Fresenius SE KGaA management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

6.5yrs

Average Tenure

60yo

Average Age

The tenure for the Fresenius SE KGaA board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Stephan Sturm (56yo)

    CEO, President & Chairman of Management Board - Fresenius Management SE

    • Tenure: 3.2yrs
    • Compensation: €6.03m
  • Ernst Wastler (60yo)

    Member of Management Board - Fresenius Management SE

    • Tenure: 11.7yrs
    • Compensation: €2.99m
  • Francesco De Meo (55yo)

    Member of Management Board - Fresenius Management SE

    • Tenure: 11.7yrs
    • Compensation: €3.81m
  • Jürgen Götz (55yo)

    Chief Legal & Compliance Officer & Labor Relations Director and Member of Management Board - GP

    • Tenure: 12.2yrs
    • Compensation: €3.02m
  • Mats Henriksson (52yo)

    Member of Management Board - Fresenius Management SE

    • Tenure: 6.7yrs
    • Compensation: €3.69m
  • Rachel Empey (43yo)

    CFO & Member of Management Board - Fresenius Management SE

    • Tenure: 2.1yrs
    • Compensation: €2.94m
  • Rice Powell (64yo)

    Member of Management Board - Fresenius Management SE

    • Tenure: 6.7yrs
    • Compensation: €6.63m
  • Markus Georgi

    Senior Vice President of Investor Relations

    • Tenure: 4.4yrs

Board Members

  • Gerd Krick (81yo)

    Chairman of Supervisory Board

    • Tenure: 16.7yrs
    • Compensation: €640.00k
  • Klaus-Peter Müller (75yo)

    Member of Supervisory Board

    • Tenure: 11.3yrs
    • Compensation: €340.00k
  • Mike Diekmann (65yo)

    Deputy Chairman of the Supervisory Board

    • Tenure: 4.3yrs
    • Compensation: €375.00k
  • Konrad Kölbl (60yo)

    Member of Supervisory Board

    • Tenure: 12.2yrs
    • Compensation: €320.00k
  • Niko Stumpfögger

    Deputy Chairman of the Supervisory Board

    • Tenure: 12.2yrs
    • Compensation: €382.00k
  • D. Albrecht (70yo)

    Member of Supervisory Board

    • Tenure: 8.7yrs
    • Compensation: €300.00k
  • Iris Löw-Friedrich (59yo)

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €300.00k
  • Stefanie Lang (51yo)

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €300.00k
  • Frauke Lehmann (56yo)

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €300.00k
  • Oscar De Paco (45yo)

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €300.00k

Company Information

Fresenius SE & Co. KGaA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fresenius SE & Co. KGaA
  • Ticker: FSNU.F
  • Exchange: OTCPK
  • Founded: 1912
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: €25.145b
  • Listing Market Cap: €27.800b
  • Shares outstanding: 557.11m
  • Website: https://www.fresenius.com

Number of Employees


Location

  • Fresenius SE & Co. KGaA
  • Else-Kröner-Strasse 1
  • Bad Homburg vor der Höhe
  • Hessen
  • 61352
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FREBRSE (Berne Stock Exchange)YesBearer Ordinary SharesCHCHFNov 1992
FREDB (Deutsche Boerse AG)YesBearer Ordinary SharesDEEURNov 1992
FREXTRA (XETRA Trading Platform)YesBearer Ordinary SharesDEEURNov 1992
0OO9LSE (London Stock Exchange)YesBearer Ordinary SharesGBEURNov 1992
FRE NBMV (Bolsa Mexicana de Valores)YesBearer Ordinary SharesMXMXNNov 1992
FREDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer Ordinary SharesGBEURNov 1992
FSNU.FOTCPK (Pink Sheets LLC)YesBearer Ordinary SharesUSUSDNov 1992
FREBIT (Borsa Italiana)YesBearer Ordinary SharesITEURNov 1992
FREWBAG (Wiener Boerse AG)YesBearer Ordinary SharesATEURNov 1992
FREADB (Deutsche Boerse AG)SPON ADR EA REP 0.125 ORD SHSDEEUROct 2011
FSNU.YOTCPK (Pink Sheets LLC)SPON ADR EA REP 0.125 ORD SHSUSUSDOct 2011
FRENMUN (Boerse Muenchen)NPV (NEW SHS)DEEURJan 2019

Biography

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Ca ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 00:15
End of Day Share Price2019/08/26 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.